Archive | January, 2010
Clinical Trial Results for H1N1 Vaccine Expected Soon (NASDAQ:NVAX)
On December 2, 2009 Novavax, Inc. (NASDAQ:NVAX) announced that it has received encouraging primary data from the first stage of the Phase 2 trial. The trial is being carried out on the company’s newly developed vaccine that is intended to be used to get immunogenicity from H1N1 virus like particle (VLP) pandemic influenza, which is [...]
Continue reading...FDA’s response on Troponin Assay Anticipated (NASDAQ:NSPH)
30 January 2010 – 5:15 pm PST
Nanosphere Inc. (NASDAQ:NSPH) is a pharmaceutical company that develops, manufactures and then brings into market “advanced molecular diagnostics systems†which detect “multiplexed direct genomic and ultra-sensitive protein detectionâ€. All its products are based on the company’s trademark Verigone(R) system. It has developed troponin assay especially for the flu season and has submitted an application to [...]
Continue reading...AspenBio Pharma’s Meeting with FDA anticipated Soon (NASDAQ:APPY)
30 January 2010 – 5:14 pm PST
Comments Off
On December 29, 2009, AspenBio Pharma, Inc. (NASDAQ: APPY), which is a growing bio science company that develops innovative tests and drugs for the betterment of mankind, disclosed information about the Premarket Notification 510(K) that it had submitted to the United States of America’s toughest regulator the Food & Drug Administration.
Continue reading...Results of XL765 Clinical Trial Expected on January 31 (NASDAQ:EXEL)
30 January 2010 – 2:55 pm PST
Comments Off
On June 1, 2009, Exelixis, Inc. (NASDAQ:EXEL) announced that they received favorable results from the Phase 1 trial of XL765. The trial dealt with finding the effects of increasing the dose of XL765. XL765 is an innovative drug that is being co-developed by Exelixis Inc. and Sanofi Aventis. Â
Continue reading...More details of Phase 2 trial of TH-302 expected soon(NASDAQ:THLD)
30 January 2010 – 2:54 pm PST
Comments Off
Hypoxia Activated Prodrug (also called HAP in short) is a type of anti cancer drug that is used by patients suffering from Tumor Hypoxia. This is condition where there is a lack of oxygen in the tumor cells. Hypoxia Activated Prodrug drugs treat levels of hypoxia (that is, low levels of oxygen) found in tumor [...]
Continue reading...Merck hopes to resubmit the NDA for Cladribine January 31 (NASDAQ:MKGAY)
30 January 2010 – 2:53 pm PST
Comments Off
Cladribine Tablets is a drug for young adults, especially females, who are suffering from multiple sclerosis (MS), which is a neurological disorder that affects the nerve cells in the spinal cord and the brain. The drug has been developed by Merck KGaA (NASDAQ:MKGAY.PK). Merck KGaA is a German-based pharmaceutical company.
Continue reading...FDA response for ACT anticipated on January 31 (NASDAQ:ACTC)
30 January 2010 – 2:51 pm PST
On November 19, 2009, Advanced Cell Technology, Inc. (NASDAQ: ACTC.OB), which is a biotechnology company that uses cloning techniques to develop a number of life-saving drugs, disclosed that the company has sent an Investigational New Drug (IND) Application to the Food and Drug Administration (FDA).
Continue reading...Acura (NASDAQ:ACUR) and King (NASDAQ:KG) expected to meet with FDA January 31
30 January 2010 – 10:55 am PST
Comments Off
Acurox (containing a combination of oxycodone HCL ad niacin) is a drug that – through the use of Aversion Technology – aims to alleviate moderate and severe pain, and to prevent various misuse and abuse techniques (such as injection of tablets into the veins, taking crushed tablets through the nose, and consuming excess tablets through [...]
Continue reading...Phase 1 clinical trial results expected on January 31, 2010 (Nasdaq:ACHN)
30 January 2010 – 10:45 am PST
On December 15, 2009, Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) disclosed some crucial information from the initial results of the second stage of the Phase 1 trial.
Continue reading...Stedesa PDUFA date extended 3 months to April 30, 2010 (NASDAQ:SEPR), (TYO:4506)
30 January 2010 – 10:44 am PST
Comments Off
Stedesa (eslicarbazepine acetate) is a drug for adults who are suffering from epilepsy, which is a chronic and common neurological disorder that causes frequent seizures. This drug has been developed by Sepracor Inc. (NASDAQ:SEPR).
Continue reading...
30 January 2010 – 5:17 pm PST
Comments Off